Industry News/Therapy

Company Launches Proleukin in Canada for Cancer Treatment

Published in Cancer Weekly, May 1st, 1995

Ligand Pharmaceuticals Inc., San Diego, California, announced the launch in Canada of Proleukin (aldesleukin) (human recombinant interleukin-2 product), a genetically engineered protein for the treatment of metastatic renal cell carcinoma, also known as metastatic kidney cancer.

The company will also launch Photofrin, porfimer sodium, in Canada for the treatment of superficial bladder cancer later in 1995. Both drugs will be marketed through its newly formed subsidiary, Ligand Pharmaceuticals (Canada) Inc. (LCI).

"Ligand has established its business presence in Canada through the exclusive licensing of its first two anticancer products. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-05-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry